{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:55Z","timestamp":1790880715988,"version":"4.1.0"},"reference-count":27,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidradenitis suppurativa (HS). The breakout of biosimilar drugs made them more accessible due to their impact on pharmacoeconomics. However, packaging, formulation, or excipients are unique characteristics of each drug. In that way, switching from adalimumab originator to biosimilar and between biosimilars could have implications in the clinical practice. The objective of this study is to describe our clinical experience in switching from adalimumab originator to biosimilar and switching back again. A single-center retrospective cohort study was conducted that included seventeen patients with HS treated with adalimumab originator in the maintenance phase, and that achieved Hidradenitis Suppurativa Clinical Response (HiSCR), who were switched to adalimumab biosimilar for no medical reasons. The reason for the change was to improve pharmacoeconomic efficiency, following our hospital policies on biologics. Median duration with adalimumab originator treatment before switching was 48 weeks. After switching, 41.2% of patients maintained HiSCR response without additional issues, while 58.8% (10\/17) reported problems after the change. Switching from adalimumab originator to biosimilar in well-controlled patients could imply problems in efficacy and adherence. Switching back to adalimumab originator appears to solve most of the problems, but some patients can lose confidence in the drug and discontinue it. It would be worthwhile to evaluate the benefit\u2013risk ratio individually when switching an HS patient to adalimumab biosimilar.<\/jats:p>","DOI":"10.3390\/jcm11041007","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:44:47Z","timestamp":1644965087000},"page":"1007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4035-7955","authenticated-orcid":false,"given":"Trinidad","family":"Montero-Vilchez","sequence":"first","affiliation":[{"name":"Hidradenitis Suppurativa Clinic, Dermatology, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-4931","authenticated-orcid":false,"given":"Carlos","family":"Cuenca-Barrales","sequence":"additional","affiliation":[{"name":"Hidradenitis Suppurativa Clinic, Dermatology, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rodriguez-Tejero","sequence":"additional","affiliation":[{"name":"Hidradenitis Suppurativa Clinic, Dermatology, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"Hidradenitis Suppurativa Clinic, Dermatology, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada, 18012 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1435","authenticated-orcid":false,"given":"Salvador","family":"Arias-Santiago","sequence":"additional","affiliation":[{"name":"Hidradenitis Suppurativa Clinic, Dermatology, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada, 18012 Granada, Spain"},{"name":"Dermatology Department, Faculty of Medicine, University of Granada, 18011 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-2113","authenticated-orcid":false,"given":"Alejandro","family":"Molina-Leyva","sequence":"additional","affiliation":[{"name":"Hidradenitis Suppurativa Clinic, Dermatology, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada, 18012 Granada, Spain"},{"name":"European Hidradenitis Suppurativa Foundation (EHSF), 06847 Dessau-Ro\u00dflau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice. Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): A novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","unstructured":"US Food and Drug Administration (2008, April 08). HUMIRA\u00ae (adalimumab) Injection, for Subcutaneous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125057s0110lbl.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ad.2015.07.006","article-title":"Model for assessing the efficiency of biologic drugs in the treatment of moderate to severe psoriasis for one year in clinical practice in Spain","volume":"107","author":"Puig","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","article-title":"The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases","volume":"80","author":"Kim","year":"2020","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamadermatol.2021.0219","article-title":"Biosimilars in Dermatology","volume":"157","author":"Lebwohl","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_7","unstructured":"Center for Drug Evaluation and Research, FDA (2008, January 31). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/14712598.2019.1636963","article-title":"Biosimilars for the treatment of psoriasis","volume":"19","author":"Puig","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","article-title":"Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases","volume":"15","author":"Papamichael","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-019-00394-x","article-title":"Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents","volume":"34","author":"Strand","year":"2019","journal-title":"BioDrugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-019-0358-2","article-title":"Compensated Hydroxyl Radical Protein Footprinting Measures Buffer and Excipient Effects on Conformation and Aggregation in an Adalimumab Biosimilar","volume":"21","author":"Misra","year":"2019","journal-title":"AAPS J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/annrheumdis-2020-eular.2561","article-title":"\u2018Switch Me If You Can\u2019\u2014Real Life Experience of Swithching to Biosimilar Drugs from Gartnavel General Hospital, Glasgow, UK","volume":"79","author":"Abdullah","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40744-020-00256-x","article-title":"Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States","volume":"8","author":"Bergman","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1136\/annrheumdis-2020-eular.3880","article-title":"AB1343-HPR A qualitative review assessing thematic outcomes from the pharmacy-led adalimumab biosimilar switch plan across 3 specialities; rheumatology, gastroenterology and dermatology at university hospitals of coventry and warwickshire (uhcw)","volume":"79","author":"Gohil","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1136\/annrheumdis-2020-eular.4709","article-title":"AB1178 An audit of originator adalimumab to biosimilar switch in two hospitals","volume":"79","author":"Mazumder","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/annrheumdis-2020-eular.1951","article-title":"AB0326 Real-world experience on switching adalimumab originator to biosimilar in inflammatory arthritis\u2014A retrospective study","volume":"79","author":"Yeoh","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-017-0658-4","article-title":"Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician","volume":"19","author":"Moots","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S438","DOI":"10.1093\/ecco-jcc\/jjz203.634","article-title":"P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: Real-world experience","volume":"14","author":"Rosembert","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjd.18220","article-title":"AURIEL-PsO: A randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"182","author":"Hercogova","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Montero-Vilchez, T., Salvador-Rodriguez, L., Sanchez-Diaz, M., Cuenca-Barrales, C., Martinez-Lopez, A., Arias-Santiago, S., and Molina-Leyva, A. (2020). Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice. Dermatol. Ther., 33.","DOI":"10.1111\/dth.14254"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.semarthrit.2015.04.002","article-title":"Clinical trial development for biosimilars","volume":"44","author":"Alten","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e14387","DOI":"10.1111\/dth.14387","article-title":"Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa","volume":"33","author":"Ricceri","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4103\/ijdvl.IJDVL_232_18","article-title":"Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa","volume":"84","author":"Patil","year":"2018","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2021.0220","article-title":"Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-abda Therapy for Patients With Hidradenitis Suppurativa","volume":"157","author":"Westerkam","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.17235\/reed.2020.6693\/2019","article-title":"Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn\u2019s disease: An observational study","volume":"112","author":"Ribaldone","year":"2020","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2020.09.039","article-title":"Pain management in hidradenitis suppurativa and a proposed treatment algorithm","volume":"85","author":"Savage","year":"2020","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/4\/1007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:20:05Z","timestamp":1760134805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/4\/1007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jcm11041007"],"URL":"https:\/\/doi.org\/10.3390\/jcm11041007","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}